Cargando…

A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines

Background: The development of a medicine is not only underpinned by good science but also by Quality DecisionMaking Practices (QDMPs). Indeed, it is important to ensure that all organisations involved in the lifecycle of medicines are aligning their practices in decision-making to the QDMPs to ensu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bujar, Magdalena, McAuslane, Neil, Walker, Stuart, Salek, Sam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kerman University of Medical Sciences 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278608/ https://www.ncbi.nlm.nih.gov/pubmed/32610811 http://dx.doi.org/10.34172/ijhpm.2020.86

Ejemplares similares

The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2019)

Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017)

Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation
por: Bujar, Magdalena, et al.
Publicado: (2020)

Implementation of a Framework for an Abridged Review Using Good Reliance Practices: Optimising the Medicine Regulatory Review Process in South Africa
por: Keyter, Andrea, et al.
Publicado: (2020)

Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities
por: McAuslane, Neil, et al.
Publicado: (2023)

The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions
por: Bujar, Magdalena, et al.
Publicado: (2021)

To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016
por: Kühler, Thomas Christian, et al.
Publicado: (2019)

Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020)

An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017–2018 using the OpERA methodology
por: Liberti, Lawrence, et al.
Publicado: (2020)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality
por: Hashan, Hajed M., et al.
Publicado: (2022)

The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making
por: Donelan, Ronan, et al.
Publicado: (2016)

A practical approach to communicating benefit-risk decisions of medicines to stakeholders
por: Leong, James, et al.
Publicado: (2015)

Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
por: Detiček, Andreja, et al.
Publicado: (2018)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

An Evaluation of Malaysian Regulatory Process for New Active Substances Approved in 2017 Using the OpERA Methodology
por: Sani, Noraisyah Mohd, et al.
Publicado: (2020)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
por: Wang, Ting, et al.
Publicado: (2020)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

“Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions
por: Jamshidi, Hamid Reza, et al.
Publicado: (2014)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
por: Salek, Sam, et al.
Publicado: (2019)

Reimbursement decision-making system in Poland systematically compared to other countries
por: Mela, Aneta, et al.
Publicado: (2023)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Informed decision‐making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments
por: Weir, Christopher J., et al.
Publicado: (2022)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?
por: Morton, Alec, et al.
Publicado: (2019)

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
por: Lux, Michael Patrick, et al.
Publicado: (2021)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Better decision making practices and processes.
por: Flack, Felicity, et al.
Publicado: (2022)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011)

Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities
por: Sithole, Tariro, et al.
Publicado: (2021)

Stratified Medicine and Reimbursement Issues
por: Fugel, Hans-Joerg, et al.
Publicado: (2012)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland
por: Keyter, Andrea, et al.
Publicado: (2019)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
por: Polisena, Julie, et al.
Publicado: (2017)

Responding to measles outbreaks in underserved Roma and Romanian populations in England: the critical role of community understanding and engagement
por: Bell, Sadie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oq9msm28veqngce7nlgn9erjp5